Imaging > 항암유효성평가지원센터

It has established a multidisciplinary bioimaging service system to speed up and efficiency of new drug development and has a image-based PK/PD evaluation, pharmacological evaluation, and validation platform, providing life-cycle bioimaging services through customized modeling.

Equipment and techniques

* Marked radioactive drugs are determined whether to proceed or not after sufficient discussion with the PET core room.

TYPE OF IMAGING

Classification

Target/Mechanism

Optical (evaluation of tumor size and treatment effect)

Evaluation of cancer transition and treatment effects through bioluminescence imaging

Efficacy evaluation of drug by imaging cell death

Nuclear medicine, PET(metabolic and functional evaluation of tumors

[18F]FDG Glucose metabolism
[18F]FLT * DNA replication
[18F]FMISO * Hypoxia
[18F]FES * Estrogen receptor
[18F]FDOPA/[18F]FET * Amino acid metabolism
[68Ga]DOTATOC Somatostatin receptor

Magnetic resonance, MRI (tumor size and function evaluation)

T1w/T2w/PD Lesion imaging of Solid tumor, Measurement of T1/T2/T2* mapping-Volume
DWI Diffusion weighted imaging , Tissue/Cellularity 측정
DCE, DSC, FAIR Dynamic Contrast Enhanced, Dynamic Susceptibility Contrast Blood flow (Angiogenetic imaging)
1H MR spectroscopy Metabolic imaging

Service

  • Customized test design
  • in vitro/in vivo/ex vivo imaging
  • Tumor growth inhibition test
  • MOA & POC verification
  • PD/PK evaluation based on fluorescence imaging
  • Immunoprofiling
  • Evaluation of tumor microenvironment with multiplex IHC
사진

Service example (tumor follow-up observation using imaging)

사진
  • Animal : Mouse
    [Chemical induced hepatocellular carcinoma]
  • 9.4T MRI[Acial, T2w Images]
  • Monitoring for 5 months (Tumor growth]

Liver cancer imaging using MRI

[18F]FDG, MC38 model

사진

Before treatment

사진

After treatment

Optical imaging of lung metastases